These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 21166699

  • 1. Therapeutic potential of CAMPATH-1H in skeletal tumours.
    Fritsche-Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser KD, Schlag PM, Kasper HU, Krenn V, Sers C.
    Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
    [Abstract] [Full Text] [Related]

  • 2. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
    Cancer Res; 2003 Oct 01; 63(19):6453-7. PubMed ID: 14559836
    [Abstract] [Full Text] [Related]

  • 3. Campath-1H treatment of multiple sclerosis.
    Jones JL, Coles AJ.
    Neurodegener Dis; 2008 Oct 01; 5(1):27-31. PubMed ID: 18075272
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 01; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 5. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb 01; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.
    Clin Cancer Res; 2008 Jan 15; 14(2):569-78. PubMed ID: 18223233
    [Abstract] [Full Text] [Related]

  • 8. 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
    James LC, Hale G, Waldmann H, Bloomer AC.
    J Mol Biol; 1999 Jun 04; 289(2):293-301. PubMed ID: 10366506
    [Abstract] [Full Text] [Related]

  • 9. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
    Golay J, Cortiana C, Manganini M, Cazzaniga G, Salvi A, Spinelli O, Bassan R, Barbui T, Biondi A, Rambaldi A, Introna M.
    Haematologica; 2006 Mar 04; 91(3):322-30. PubMed ID: 16531255
    [Abstract] [Full Text] [Related]

  • 10. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
    Taylor VC, Sims M, Brett S, Field MC.
    Biochem J; 1997 Mar 15; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
    [Abstract] [Full Text] [Related]

  • 11. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A, Lowenstein H, Chant A, Khan A.
    Transpl Int; 2006 Sep 15; 19(9):749-58. PubMed ID: 16918536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CD52 antigen may be a therapeutic target for eosinophilic rhinosinusitis.
    Zhang PL, Pennington JR, Prichard JW, Blasick TM, Brown AM, Potdar S.
    Ann Clin Lab Sci; 2007 Sep 15; 37(2):148-51. PubMed ID: 17522370
    [Abstract] [Full Text] [Related]

  • 15. Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
    Guyre CA, Gomes D, Smith KA, Kaplan JM, Perricone MA.
    J Immunol Methods; 2008 Apr 20; 333(1-2):51-60. PubMed ID: 18314132
    [Abstract] [Full Text] [Related]

  • 16. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL.
    Clin Cancer Res; 2006 Dec 01; 12(23):7174-9. PubMed ID: 17145843
    [Abstract] [Full Text] [Related]

  • 17. Effect of alemtuzumab on neoplastic B cells.
    Golay J, Manganini M, Rambaldi A, Introna M.
    Haematologica; 2004 Dec 01; 89(12):1476-83. PubMed ID: 15590398
    [Abstract] [Full Text] [Related]

  • 18. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa.
    Focarelli R, Francavilla S, Francavilla F, Della Giovampaola C, Santucci A, Rosati F.
    Mol Hum Reprod; 1999 Jan 01; 5(1):46-51. PubMed ID: 10050661
    [Abstract] [Full Text] [Related]

  • 19. CD52 antigen--a review.
    Domagała A, Kurpisz M.
    Med Sci Monit; 2001 Jan 01; 7(2):325-31. PubMed ID: 11257744
    [Abstract] [Full Text] [Related]

  • 20. Epitope analysis of immunoglobulins against gp20, a GPI-anchored protein of the human sperm surface homologous to leukocyte antigen CD52.
    Flori F, Giovampaola CD, Focarelli R, Secciani F, La Sala GB, Nicoli A, Hale G, Rosati F.
    Tissue Antigens; 2005 Sep 01; 66(3):209-16. PubMed ID: 16101832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.